New Obesity Framework Flags Hidden Organ Damage in Mexican Children That BMI Misses

Body mass index has been the workhorse of pediatric obesity diagnosis for decades, but a new study from Mexico suggests it may be quietly missing some of the children who need help most. Researchers at a pediatric obesity clinic in northeastern Mexico compared the familiar CDC BMI criteria with the Clinical Framework of Obesity 2025, a new diagnostic approach proposed by The Lancet Diabetes & Endocrinology Commission, and found that the two systems told strikingly different stories about the same children. The findings, published in Pediatric Research, add to a growing international debate about whether a single number calculated from height and weight can really capture what obesity does to a growing body.

The study team, led by Judith E. Guzmán-García of the Pediatric Obesity Clinic at Hospital Regional Materno Infantil and Tecnológico de Monterrey, analyzed 220 patients aged 4 to 16 years who attended the clinic in northeastern Mexico. This was a cross-sectional study, meaning the researchers assessed each child at a single point in time rather than following them over months or years. Every child was classified twice: once using the Centers for Disease Control and Prevention BMI criteria, the standard percentile-based approach familiar to pediatricians worldwide, and once using the Clinical Framework of Obesity 2025, adapted for pediatric use. Under the new framework, children were categorized as having preclinical or clinical obesity depending on whether their excess adiposity was already causing measurable organ-system dysfunction.

The headline result is a substantial gap between the two diagnostic systems. By CDC BMI criteria, 80 percent of the children met the definition of obesity. Under the Clinical Framework of Obesity 2025, that figure rose to 95 percent. The researchers quantified the agreement between the two systems using Cohen’s kappa, a statistical measure that corrects for chance agreement, and found only fair concordance, with a kappa of 0.321 and a p value below 0.001. In practical terms, this means the two frameworks were not simply interchangeable labels for the same phenomenon; they were identifying meaningfully different groups of children as having obesity.

Perhaps the most consequential finding concerns the children that BMI alone would wave through. Clinical obesity, the state in which excess fat is actively damaging organs, was identified in 83.2 percent of the patients under the new framework, and this included children whom the CDC BMI criteria classified as having normal weight or merely overweight. In other words, some children sitting in the supposedly reassuring middle of the BMI chart were already showing signs of obesity-related organ dysfunction. For clinicians who rely on BMI as a screening gatekeeper, that is a sobering result, because those children might never be referred for the metabolic workups that could catch problems early.

Which organ systems were suffering? The metabolic system topped the list, affected in 73.2 percent of the children classified with clinical obesity, followed by the cardiovascular system at 59 percent. These are not trivial findings. Metabolic abnormalities in childhood, such as insulin resistance and dyslipidemia, are well-documented precursors of type 2 diabetes and cardiovascular disease in adulthood, and longitudinal research has shown that risk factors like elevated blood pressure and adverse lipid profiles tend to track from childhood into adult life. The study’s authors note that the framework’s ability to surface this multisystem involvement, even among children with BMI values in the normal or overweight range, is precisely what makes it a potentially valuable complement to conventional anthropometric screening.

The Clinical Framework of Obesity 2025 emerged from a Lancet Commission that sought to redefine obesity not as a body-size category but as a medical condition, one that can exist without illness or can cause overt organ dysfunction. The commission distinguished between preclinical obesity, where excess adiposity is present but organs are still functioning normally, and clinical obesity, where the fat mass itself is driving disease. This conceptual shift matters because it moves the diagnostic question away from how heavy a child is relative to peers and toward what the excess fat is actually doing to the body. In adults, the new definition has already been tested in large cohorts in the United States and Peru, with studies reporting that it reclassifies substantial numbers of people. The Mexican study is among the first to apply the framework, with pediatric adaptations, to a clinical population of children.

Mexico provides a particularly urgent setting for this kind of research. National survey data published in Salud Pública de México show high rates of overweight and obesity among Mexican schoolchildren and adolescents, and global forecasting studies project that childhood obesity will continue to climb worldwide through mid-century. Children with obesity face elevated risks of comorbidities ranging from fatty liver disease, which has been linked to serious liver outcomes in adolescence and young adulthood, to psychosocial difficulties and limitations in daily physical activities. Against that backdrop, a diagnostic tool that better identifies which children are already experiencing organ damage could help clinics triage limited resources toward those at greatest immediate risk.

The authors are careful about the limits of their work, and readers should be too. The Clinical Framework of Obesity 2025 has not yet been validated in pediatric populations, and this study offers preliminary evidence rather than a definitive endorsement. The sample came from a single referral clinic in northeastern Mexico, meaning the children were already selected for concern about weight or metabolic health, so the prevalence figures cannot be generalized to the broader population of Mexican children. The cross-sectional design captures a snapshot rather than a trajectory, so the study cannot say whether children classified as having preclinical obesity would go on to develop clinical disease. The requirement for individual informed consent was waived by the hospital’s ethics committee and the Nuevo León Ministry of Health because the study was retrospective and used de-identified data, and the authors report no competing interests and no external funding.

There is also a live scientific debate about the new definition itself. Commentators in JAMA Network Open and JAMA Pediatrics have questioned whether the new criteria define too many people as obese, with some arguing that expanding the diagnostic umbrella risks pathologizing body sizes without clear evidence of harm, while others counter that the framework finally acknowledges that BMI is an imperfect proxy for adiposity and its consequences. Studies of BMI’s diagnostic performance have long shown that it can miss children with excess fat mass and elevated cardiometabolic risk, and systematic reviews comparing bioelectrical impedance with dual X-ray absorptiometry in pediatric populations highlight how difficult it remains to measure adiposity accurately in children. The Mexican study sits squarely in this contested territory, and its fair kappa value is less a verdict on either system than a demonstration that they are measuring different things.

The practical takeaway from the study is not that BMI should be abandoned, but that it may be insufficient on its own. The authors conclude that applying the Clinical Framework of Obesity 2025 alongside BMI identified additional multisystem involvement that BMI-based classification alone would have overlooked, and they suggest that integrating the two may support a more structured and comprehensive assessment of obesity-related organ involvement in children. For a field in which childhood obesity is increasingly framed as a chronic disease demanding specific health care, that reframing could change how pediatric clinics evaluate their patients: not just how heavy they are, but whether their hearts, livers, and metabolisms are already paying the price. Validation studies in larger and more diverse pediatric populations will be needed before the framework becomes standard practice, but this preliminary evidence from Monterrey suggests that the era of diagnosing childhood obesity with a single calculated number may be drawing to a close.

Subject of Research: Comparison of CDC BMI criteria and the Clinical Framework of Obesity 2025 for diagnosing obesity and organ-system involvement in Mexican children

Article Title: Comparing two diagnostic frameworks for obesity in Mexican children attending a pediatric obesity clinic

Article References: Guzmán-García, J. E., Gomez-Orozco, P., Velasco-Rodríguez, V. M., Martínez-Tapia, M. E., & Rodríguez-Gutiérrez, N. A. (2026). Comparing two diagnostic frameworks for obesity in Mexican children attending a pediatric obesity clinic. Pediatric Research. https://doi.org/10.1038/s41390-026-05479-2

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05479-2

Keywords: pediatric obesity, body mass index, Clinical Framework of Obesity 2025, CDC BMI criteria, clinical obesity, preclinical obesity, metabolic dysfunction, cardiovascular risk, Mexican children, organ-system involvement, diagnostic criteria, Pediatric Research